These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6365273)

  • 41. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer.
    Howell SB
    Int J Gynecol Cancer; 2008; 18 Suppl 1():20-5. PubMed ID: 18336394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
    Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
    N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy of breast cancer: current views and results.
    Bonadonna G; Valagussa P
    Int J Radiat Oncol Biol Phys; 1983 Mar; 9(3):279-97. PubMed ID: 6341335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Bone metastasis of breast cancer. Apropos of a series of 50 cases].
    Vincent-Joyeux F; Bontoux D; Alcalay M; Daban A; Vincent D
    Sem Hop; 1982 Dec; 58(48):2827-31. PubMed ID: 6302849
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
    Greco FA; Julian CG; Richardson RL; Burnett L; Hande KR; Oldham RK
    Obstet Gynecol; 1981 Aug; 58(2):199-205. PubMed ID: 6789265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Chemotherapy of ovarian carcinoma].
    Pfleiderer A
    Strahlentherapie; 1982 Dec; 158(12):708-16. PubMed ID: 6891844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas.
    Roboz J; Jacobs AJ; Holland JF; Deppe G; Cohen CJ
    Med Pediatr Oncol; 1981; 9(3):245-50. PubMed ID: 7242462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Principle products used in chemotherapy. Administration methods].
    Boillon C; Olivro A; Lemerle J
    Soins; 1979 Aug 5-20; 24(15-16):51-9. PubMed ID: 90390
    [No Abstract]   [Full Text] [Related]  

  • 49. [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
    Israël L; Lepage E; Breau JL; Aguilera J
    Bull Cancer; 1982; 69(5):426-33. PubMed ID: 6891902
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Malignant teratoma of the ovary: prognostic factors and treatment.
    Curry SL; Smith JP; Gallagher HS
    Am J Obstet Gynecol; 1978 Aug; 131(8):845-9. PubMed ID: 686082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.
    de Bree E; Helm CW
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):895-911. PubMed ID: 22845405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platinum-based combination chemotherapy in non-small cell lung carcinoma.
    Takita H; Edgerton F; Marabella P; Conway D; Harguindey S
    Cancer; 1981 Oct; 48(7):1528-30. PubMed ID: 7197188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
    Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
    Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.
    Tranum BL; McDonald B; Thigpen T; Vaughn C; Wilson H; Maloney T; Costanzi J; Bickers J; el Mawli NG; Palmer R; Hoogstraten B; Heilburn L; Rasmusen S
    Cancer; 1982 Mar; 49(5):835-9. PubMed ID: 7037152
    [No Abstract]   [Full Text] [Related]  

  • 56. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
    Piver MS; Lele S; Barlow JJ
    Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Four drug combination cytotoxic chemotherapy following surgery for breast cancer.
    Edelstyn GA; Bates IS; Brinkley D; MacRae KD; Spittle H; Wheeler T
    Recent Results Cancer Res; 1978; 68():109-12. PubMed ID: 752851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.
    Piver MS; Barlow JJ; Bhattacharya M
    Cancer Treat Rep; 1979 Feb; 63(2):265-7. PubMed ID: 376133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy.
    Regelson W; Parker G
    Cancer Invest; 1986; 4(1):29-42. PubMed ID: 3082469
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.